A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia

Oshima, Yuri; Matsuura, Hiroyuki; Sakurai, Yusuke; Hirai, Kaho; Tani, Eriko; Yoshimoto, Noriko; Minami, Kenichi; Yamasaki, Fumio; Nishime, Mayu; Hirashima, Tomonori

doi:10.1016/j.rmcr.2022.101609

Cited by 3 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 However, a collaborative, multidisciplinary approach that combines the use of anamorelin with the expertise of nutritionists and physical therapists may enhance physical function in some patients with cancer cachexia. 24…”

Section: Discussionmentioning

confidence: 99%

The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials

Rezaei

Oliveira

Ghanavati

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background Cachexia is associated with increased morbidity and mortality rates in patients with cancer. This meta-analysis aims to explore the effect of anamorelin on cancer cachexia markers. Methods We searched MEDLINE/PubMed, SCOPUS, and WOS from their inception until 5 June 2022. A systematic search was conducted according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. We included trials investigating the effect of anamorelin on body weight, lean body mass, fat mass, insulin-like growth factor 1 (IGF-1), handgrip, quality of life insulin-like growth factor-binding protein 3 (IGFBP-3), and in patients with cancer. A random-effects model was run to pooled results. Results Five articles providing 1331 participants were analyzed in this study. Pooled analysis revealed a significant increase in body weight (weighted mean difference (WMD): 1.56 kg, 95% confidence interval (CI): 1.20, 1.92; I2= 0%), lean body mass (WMD: 1.36 kg, 95% CI: 0.85, 1.86; I2= 53.1%), fat mass (WMD: 1.02 kg, 95% CI: 0.51, 1.53; I2= 60.7%), IGF-1 (WMD: 51.16 ng/mL, 95% CI: 41.42, 60.90, I2= 0%), and IGFBP-3 (WMD: 0.43 μg/mL, 95% CI: 0.17, 0.68, I2= 98.6%). Results showed no significant increase in appetite when analysis run on all studies without considering different doses 0.29 (95% CI: −0.30, 0.89, I2= 73.8%), however, there was a significant increase in appetite without heterogeneity and inconsistency 0.59 (95% CI: 0.32, 0.86; I2= 0%) in the 100 mg/day group compared to anamorelin non-user. Conclusions Patients with cancer who receive anamorelin as a treatment for cachexia showed a significant increase in body weight, lean body mass, fat mass, IGF-1, and IGFBP-3.

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials

Rezaei

Oliveira

Ghanavati

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…Oshima et al . 14 reported a case of a 69-year-old man with stage IVB squamous cell lung cancer complicated by cancer cachexia. Anamorelin was combined with a treatment approach by a multidisciplinary collaboration, including registered dietitians and physical therapists.…”

Section: Recent Published Papers On Anamorelinmentioning

confidence: 99%

“…Of 28 (62%) patients evaluable at day 43, cancer-related fatigue, activity, anorexia, body weight, and lean body mass composition improved statistically from baseline. Oshima et al [14] reported a case of a 69-year-old man with stage IVB squamous cell lung cancer complicated by cancer cachexia. Anamorelin was combined with a treatment approach by a multidisciplinary collaboration, including registered dietitians and physical therapists.…”

Section: Key Pointsmentioning

confidence: 99%

Anamorelin in Japanese patients with cancer cachexia: an update

Wakabayashi

Arai

Inui

2023

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Purpose of review Anamorelin was approved for production and marketing in Japan on 22 January 2021 for cancer cachexia in non-small-cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. The authors describe the updates of anamorelin for cancer cachexia in Japan. Recent findings Recent evidence showed that anamorelin improved lean body mass, body weight, and appetite in patients with cancer cachexia in clinical practice. Anamorelin does not increase body weight in the severe-weight-loss group in cachectic patients with pancreatic cancer. Several case reports showed that anamorelin can cause cardiac adverse drug reactions. Among the cardiac adverse reactions, fatal arrhythmias should be monitored carefully even if it is the first dose. Anamorelin combined with nutrition, physical activity, and exercise may be more useful than anamorelin alone for treating cancer cachexia. An interim analysis from post-marketing all-case surveillance was performed; however, details have not yet been published. When anamorelin cannot be used for cancer cachexia, Kampo medicines can be considered as an option. Summary Anamorelin has changed the clinical practice of cancer cachexia in Japan. The authors hope that anamorelin is available for other disease-related cachexia along with appropriate multidisciplinary interventions.

show abstract

Combination therapy of corylifol A and anamorelin attenuates cachexia by decreasing pro-inflammatory cytokines, inhibiting lipolysis and increasing food intake in a murine colon cancer model

Li,

Zhang,

Deng

et al. 2024

Discov Med

View full text Add to dashboard Cite

A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia

Cited by 3 publications

References 24 publications

The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials

The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials

Anamorelin in Japanese patients with cancer cachexia: an update

Combination therapy of corylifol A and anamorelin attenuates cachexia by decreasing pro-inflammatory cytokines, inhibiting lipolysis and increasing food intake in a murine colon cancer model

Contact Info

Product

Resources

About